Audentes Therapeutics Inc (NASDAQ:BOLD) has been assigned a $24.00 price target by stock analysts at Piper Jaffray Cos. in a report released on Monday. The brokerage currently has a a “buy” rating on the stock. Piper Jaffray Cos.’s price objective indicates a potential upside of 26.58% from the stock’s current price.
A number of other research firms also recently weighed in on BOLD. Wedbush reaffirmed an “outperform” rating and set a $20.00 price objective on shares of Audentes Therapeutics in a report on Thursday, September 1st. Cowen and Company began coverage on Audentes Therapeutics in a report on Monday, August 15th. They set an “outperform” rating on the stock.
Shares of Audentes Therapeutics (NASDAQ:BOLD) opened at 18.96 on Monday. The firm’s 50-day moving average price is $15.91 and its 200 day moving average price is $15.51. The firm’s market capitalization is $411.91 million. Audentes Therapeutics has a 52 week low of $13.06 and a 52 week high of $19.37.
In other news, major shareholder Versant Ventures Iv, Llc bought 35,000 shares of the business’s stock in a transaction dated Monday, July 25th. The stock was bought at an average price of $15.00 per share, for a total transaction of $525,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider James E. Flynn bought 400,000 shares of the business’s stock in a transaction dated Monday, July 25th. The stock was purchased at an average price of $15.00 per share, with a total value of $6,000,000.00. The disclosure for this purchase can be found here.
Audentes Therapeutics Company Profile
Audentes Therapeutics, Inc is a biotechnology company. The Company focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects. Its portfolio of product candidates include AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).
Receive News & Ratings for Audentes Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.